| Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial J Diaz-Manera, PS Kishnani, H Kushlaf, S Ladha, T Mozaffar, V Straub, ... The Lancet Neurology 20 (12), 1012-1026, 2021 | 86 | 2021 |
| Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double … B Schoser, M Roberts, BJ Byrne, S Sitaraman, H Jiang, P Laforêt, ... The Lancet Neurology 20 (12), 1027-1037, 2021 | 62 | 2021 |
| Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors M Sepúlveda, C Montejo, S Llufriu, N Sola-Valls, D Reyes, ... Multiple sclerosis and related disorders 38, 101483, 2020 | 29 | 2020 |
| Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder A Iranzo, A Stefani, A Niñerola-Baizan, H Stokner, M Serradell, D Vilas, ... Neurology 94 (15), e1605-e1613, 2020 | 23 | 2020 |
| Beyond the epileptic focus: functional epileptic networks in focal epilepsy F Gil, N Padilla, S Soria-Pastor, X Setoain, T Boget, J Rumiá, P Roldán, ... Cerebral cortex 30 (4), 2338-2357, 2020 | 20 | 2020 |
| Immune response and safety of SARS-CoV-2 mRNA-1273 vaccine in patients with myasthenia gravis D Reyes-Leiva, J López-Contreras, E Moga, F Pla-Juncà, E Lynton-Pons, ... Neurology: Neuroimmunology & Neuroinflammation 9 (4), e200002, 2022 | 18 | 2022 |
| Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome E Cortés‐Vicente, R Álvarez‐Velasco, F Pla‐Junca, R Rojas‐Garcia, ... Annals of clinical and translational neurology 9 (2), 122-131, 2022 | 16 | 2022 |
| Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial PS Kishnani, J Diaz-Manera, A Toscano, PR Clemens, S Ladha, ... JAMA neurology 80 (6), 558-567, 2023 | 12 | 2023 |
| Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia M Caballero-Ávila, R Álvarez-Velasco, E Moga, R Rojas-Garcia, ... Neuromuscular Disorders 32 (8), 664-671, 2022 | 11 | 2022 |
| Motor neuron involvement expands the neuropathological phenotype of late‐onset ataxia in RFC1 mutation (CANVAS) D Reyes‐Leiva, I Aldecoa, E Gelpi, R Rojas‐García Brain Pathology 32 (4), 2022 | 10 | 2022 |
| Correlation between respiratory accessory muscles and diaphragm pillars MRI and pulmonary function test in late-onset pompe disease patients D Reyes-Leiva, J Alonso-Pérez, M Mayos, C Nuñez-Peralta, J Llauger, ... Frontiers in neurology 12, 621257, 2021 | 8 | 2021 |
| Neuroinflammation-related proteins NOD2 and spp1 are abnormally upregulated in amyotrophic lateral sclerosis N de Luna, Á Carbayo, O Dols-Icardo, J Turon-Sans, D Reyes-Leiva, ... Neurology: Neuroimmunology & Neuroinflammation 10 (2), e200072, 2022 | 7 | 2022 |
| Azathioprine therapy induces selective NK cell depletion and IFN-γ deficiency predisposing to herpesvirus reactivation F Ingelfinger, C Sparano, D Bamert, D Reyes-Leiva, A Sethi, ... Journal of Allergy and Clinical Immunology 151 (1), 280-286. e2, 2023 | 6 | 2023 |
| Pathophysiological underpinnings of extra-motor neurodegeneration in amyotrophic lateral sclerosis: new insights from biomarker studies D Reyes-Leiva, O Dols-Icardo, S Sirisi, E Cortés-Vicente, J Turon-Sans, ... Frontiers in neurology 12, 750543, 2022 | 6 | 2022 |
| Cervical spinal cord injury by a low-impact trauma as an unnoticed cause of cardiorespiratory arrest G Mayà-Casalprim, J Ortiz, A Tercero, D Reyes, Á Iranzo, J Santamaria, ... European Heart Journal-Case Reports 4 (2), 1-6, 2020 | 6 | 2020 |
| Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain F De Frutos, JP Ochoa, C Gómez-González, D Reyes-Leiva, JI Aróstegui, ... Amyloid 30 (2), 199-207, 2023 | 4 | 2023 |
| Magnetization transfer ratio in lower limbs of late onset pompe patients correlates with intramuscular fat fraction and muscle function Tests C Nuñez-Peralta, P Montesinos, A Alonso-Jiménez, J Alonso-Pérez, ... Frontiers in neurology 12, 634766, 2021 | 4 | 2021 |
| Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis R Álvarez-Velasco, O Dols-Icardo, S El Bounasri, L López-Vilaró, ... Neurology: Neuroimmunology & Neuroinflammation 10 (2), e200085, 2023 | 3 | 2023 |
| Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial R Tawil, KR Wagner, JI Hamel, DG Leung, JM Statland, LH Wang, ... The Lancet Neurology 23 (5), 477-486, 2024 | 2 | 2024 |
| High prevalence of paraspinal muscle involvement in adults with McArdle disease R Álvarez‐Velasco, CA Nuñez‐Peralta, J Alonso‐Pérez, E Gallardo, ... Muscle & Nerve 65 (5), 568-573, 2022 | 2 | 2022 |
Gerard MayàNeurólogo, Hospital Clínic de BarcelonaVerified email at clinic.cat
